Dr Ana Baramidze talks to ecancer about her EMPOWER-Lung 1 phase 3 trial.

It investigated cemiplimab, a PD-1 inhibitor, as a first-line treatment for advanced non-small-cell lung cancer (NSCLC) in patients with PD-L1 expression of at least 50%.

The study showed that cemiplimab significantly improved overall survival and progression-free survival compared to chemotherapy, with fewer severe adverse events.

These results suggest cemiplimab could offer a new treatment option for this patient population.